Details for New Drug Application (NDA): 205513
✉ Email this page to a colleague
NDA 205513 describes CARISOPRODOL, which is a drug marketed by Able, Accelrx Labs, Allied, Aurobindo Pharma, Chartwell Rx, Epic Pharma Llc, Hikma Intl Pharms, Natco, Nostrum Labs Inc, Novast Labs, Orient Pharma Co Ltd, Oxford Pharms, Pioneer Pharms, Sandoz, Sciegen Pharms Inc, Strides Pharma, Sun Pharm Inds Ltd, Sun Pharm Industries, Wanbang Biopharms, Watson Labs, Watson Labs Teva, Genus, and Ingenus Pharms Nj, and is included in thirty-two NDAs. It is available from twenty-five suppliers. Additional details are available on the CARISOPRODOL profile page.
The generic ingredient in CARISOPRODOL is aspirin; carisoprodol; codeine phosphate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; carisoprodol; codeine phosphate profile page.
The generic ingredient in CARISOPRODOL is aspirin; carisoprodol; codeine phosphate. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; carisoprodol; codeine phosphate profile page.
Summary for 205513
| Tradename: | CARISOPRODOL |
| Applicant: | Strides Pharma |
| Ingredient: | carisoprodol |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 205513
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 250MG | ||||
| Approval Date: | Nov 12, 2015 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | TABLET;ORAL | Strength | 350MG | ||||
| Approval Date: | Nov 12, 2015 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
